Aclaris Therapeutics(us:ACRS)
1.53
-3.77%
Updated on 2025-03-31
Open:1.57
Close:1.53
High:1.57
Low:1.47
Prev Close:1.59
Volume:512536.00
Turnover:777573.88
Turnover Ratio:0.47%
Shares:107.92M
MarketCap:165.12M
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 3 | 1768 | 0.00% | 0 | 1 | 1 |
| 2024-03-31 | 122 | 54435371 | 76.40% | 18 | 27 | 64 |
| 2023-12-31 | 159 | 58470842 | 82.48% | 22 | 40 | 81 |
| 2023-09-30 | 150 | 70015984 | 98.87% | 20 | 61 | 48 |
| 2023-06-30 | 157 | 71013126 | 100.34% | 11 | 51 | 67 |
| 2023-03-31 | 166 | 71531252 | 106.44% | 39 | 43 | 60 |
| 2022-12-31 | 141 | 65928699 | 98.86% | 13 | 46 | 49 |
| 2022-09-30 | 135 | 63568934 | 95.33% | 20 | 48 | 34 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-03-31 | Bml Capital Management, Llc | 9395934 | 13.19% | 8742827 | 1338.65% |
| 2024-03-31 | Blackrock Inc. | 5202147 | 7.30% | -703725 | -11.92% |
| 2024-03-31 | Vanguard Group Inc | 4929775 | 6.92% | 207418 | 4.39% |
| 2024-03-31 | D. E. Shaw & Co., Inc. | 3282982 | 4.61% | 1343972 | 69.31% |
| 2024-03-31 | Millennium Management Llc | 3273492 | 4.59% | -205869 | -5.92% |
| 2024-03-31 | Bain Capital Life Sciences Investors, Llc | 3000000 | 4.21% | -500000 | -14.29% |
| 2024-03-31 | Rock Springs Capital Management Lp | 2753495 | 3.86% | -245000 | -8.17% |
| 2024-03-31 | Acadian Asset Management Llc | 2135367 | 3.00% | -216040 | -9.19% |
| 2024-03-31 | Renaissance Technologies Llc | 1673400 | 2.35% | -73032 | -4.18% |
| 2024-03-31 | Geode Capital Management, Llc | 1565054 | 2.20% | 171506 | 12.31% |
About
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Address:701 Lee Road,Suite 103
Website:http://www.aclaristx.com
Market Movers